Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

AACC 2015: Research Expanded Upon for New Rapid Response Ebola Test

July 27, 2015 10:40 am | by Ryan Bushey, Associate Editor | Articles | Comments

The test is able to diagnose the virus in 15 minutes. Read more...

TOPICS:

Malaria's Key to the Liver Uncovered

July 27, 2015 10:18 am | News | Comments

Scientists uncover a port of liver entry for malaria parasites in a report published in The Journal of Experimental Medicine. If these results hold up in humans, drugs that target this entry protein might help prevent the spread of disease. Read more...

TOPICS:

Brain Disorder Center's Closing Sends Ripples Nationwide

July 27, 2015 10:09 am | by Kathleen Ronayne, AP | News | Comments

When Tyler Richardson's son hit puberty, the combination of hormones and new strength from a growth spurt added an element of danger to a long history of unpredictable behavior because of autism and severe anger problems. Read more...

TOPICS:
Advertisement

FDA OKs Breakthrough Cholesterol Drug for High-Risk Patients

July 27, 2015 10:03 am | by Matthew Perrone, AP Health Writer | News | Comments

The Food and Drug Administration on Friday approved a first-of-a-kind drug that lowers artery-clogging cholesterol more than older drugs that have been prescribed for decades. Read more...

TOPICS:

Scientists Win $1.5 Million to Study New Strategies for Parkinson’s Disease and Other Disorders

July 27, 2015 9:54 am | by The Scripps Research Institute | News | Comments

Scientists from the Florida campus of The Scripps Research Institute (TSRI) have been awarded nearly $1.5 million from the National Institute of General Medical Sciences of the National Institutes of Health to explore the therapeutic potential of a class of proteins that play essential roles in the regulation and maintenance of human health. Read more...

TOPICS:

Bristol-Myers Wins Approval for 1st Hepatitis C Type 3 Drug

July 27, 2015 9:50 am | by Linda A. Johnson, AP Business Writer | News | Comments

An experimental drug for one of the hardest-to-treat types of hepatitis C has been approved by the Food and Drug Administration, adding to the surge of new options - all much more effective but extremely costly - for patients with the liver-destroying virus. Read more...

TOPICS:

Allergan to Acquire Naurex

July 27, 2015 8:59 am | News | Comments

This acquisition builds on Allergan's world-class position and leadership strategy in mental health. Read more...

TOPICS:

Study Finds Non-Genetic Cancer Mechanism

July 27, 2015 8:52 am | by University of Leeds | News | Comments

The findings also open the possibility of new therapies aimed at measuring and preventing dangerous imbalances in cells. Read more...

TOPICS:
Advertisement

Molecular Clues to Serious Illnesses to Be Explored

July 27, 2015 8:47 am | by University of Manchester | News | Comments

Scientists in MMPathIC will also work with Manchester colleagues in the Manchester Cancer Research Centre to share ongoing advances that will assist in cancer diagnosis and treatment. Read more...

TOPICS:

FDA Approves Novartis' Drug for Treating Common Skin Cancer

July 27, 2015 8:39 am | by The Associated Press | News | Comments

Odomzo was approved for patients whose cancer hasn't spread to other body parts, but recurred after surgery or radiation therapy or can't be cured by those treatments. Read more...

TOPICS:

Teva Buys Allergan Generic Drug Company for $40.5B

July 27, 2015 8:35 am | by Daniel Estrin, Associated Press | News | Comments

Teva's leadership has been saying for months that it believes some of the biggest generic drug companies should combine in order to save money and become more efficient. Read more...

TOPICS:

Avanir: New Findings from Dementia Phase 2 Study

July 24, 2015 12:38 pm | News | Comments

Avanir Pharmaceuticals, Inc. today announced new findings from the dementia/Alzheimer's disease cohort of the PRISM II study, a phase IV study evaluating the safety and effectiveness of NUEDEXTA in treating pseudobulbar affect (PBA) in patients with dementia/Alzheimer's disease, stroke and traumatic brain injury (TBI). Read more...

TOPICS:

Lifestyle Changes May Guard Aging Brain Against Memory Loss

July 24, 2015 12:33 pm | by Lauren Neergaard, AP Medical Writer - Associated Press | News | Comments

The latest Alzheimer's research has a clear theme: Change your lifestyle to protect your brain. It will take several years for scientists to prove whether some experimental drugs could at least delay Alzheimer's disease, and an aging population is at risk now. Read more...

TOPICS:

Amgen Submits Supplemental NDA For Carfilzomib In Relapsed Multiple Myeloma

July 24, 2015 12:13 pm | News | Comments

Amgen today announced the submission of a supplemental New Drug Application (sNDA) to the U.S. Food and Drug Administration (FDA) for Kyprolis (carfilzomib) for Injection to seek an expanded indication for the treatment of patients with a form of blood cancer, relapsed multiple myeloma, who have received at least one prior therapy. Read more...

TOPICS:

For Prostate Cancer Patients, Risk-Specific Therapies Now More the Norm

July 24, 2015 12:09 pm | by UCSF | News | Comments

After decades of overtreatment for low-risk prostate cancer and inadequate management of its more aggressive forms, patients are now more likely to receive medical care matched to level of risk, according to a study by researchers at UC San Francisco. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading